Mutual of America Capital Management LLC has been actively adjusting its investment portfolio, according to recent filings with the Securities and Exchange Commission (SEC). These moves involve several companies in the biotechnology and technology sectors.
Cytokinetics and Lumentum Holdings: Stake Reduction
The investment firm lessened its stake in Cytokinetics, Incorporated (NASDAQ:CYTK) by 2.0% during the fourth quarter. According to their 13F filing, they sold 1,248 shares, bringing their total holdings down to 62,339 shares. Cytokinetics is a biopharmaceutical company.
Similarly, Mutual of America Capital Management LLC also reduced its holdings in Lumentum Holdings Inc. (NASDAQ:LITE). The stake was lessened by 1.1% during the same quarter. The fund sold 408 shares, leaving them with 36,290 shares of the technology company's stock. These adjustments, like the one involving Cytokinetics, were detailed in the company's recent 13F filing with the SEC.
Bio-Techne Co.: Increased Investment
In contrast to the reductions, Mutual of America Capital Management LLC increased its position in Bio-Techne Co. (NASDAQ:TECH). During the fourth quarter, the firm raised its holdings by 2.6%, now owning 42,753 shares of the biotechnology company's stock. This increase reflects a $3.08 million stake in the company, according to the same 13F filing.
Acacia Research: StockNews.com Upgrade
In other news, Acacia Research (NASDAQ:ACTG) received an upgrade from StockNews.com. Analysts at the firm moved the stock from a "sell" rating to a "hold" rating. On Wednesday, Acacia Research trading saw an increase of 2.8%, with NASDAQ ACTG opening at $4.09.
The StockNews.com note also highlighted Acacia Research's financial health, noting a quick ratio of 15.95. These ratings changes can impact investor sentiment and influence trading activity.
These adjustments reflect the dynamic nature of investment management, where firms constantly evaluate and rebalance their portfolios based on market conditions and company performance.